• Breaking News & Live Updates
  • Breaking News & Live Updates
  • Breaking News & Live Updates
  • Breaking News & Live Updates
  • Breaking News & Live Updates
  • Breaking News & Live Updates
  • Breaking News & Live Updates
  • Breaking News & Live Updates
  • Breaking News & Live Updates
  • Breaking News & Live Updates
Home/Money/Jim Cramer Recommends Kimberly-Clark with a 5.25% Yield
Money

Jim Cramer Recommends Kimberly-Clark with a 5.25% Yield

T. Harv Eker
authorBy T. Harv Eker
dateApr 12, 2026
Read time3 min

Prominent financial commentator Jim Cramer has voiced his strong support for Kimberly-Clark Corporation, highlighting its impressive 5.25% dividend yield. His recommendation comes despite a recent operational challenge, specifically a major fire at one of the company's key distribution centers. Cramer views this as a temporary setback and, coupled with the strategic acquisition of Kenvue, believes these factors collectively position Kimberly-Clark as an attractive investment, even with its current valuation at 13 times earnings. He explicitly advises investors to consider increasing their holdings in KMB, expressing significant confidence in the leadership of CEO Mike Hsu.

Financial Expert Endorses Kimberly-Clark Amidst Market Dynamics

On Sunday, April 12, 2026, during a segment of his popular financial program, renowned market analyst Jim Cramer offered a definitive endorsement of Kimberly-Clark Corporation (KMB). When queried by a viewer regarding the stock's prospects, Cramer enthusiastically declared his desire to own KMB, particularly noting its robust 5.25% dividend yield. He acknowledged the recent six-alarm fire at the company's largest toilet paper distribution center but quickly dismissed its long-term impact, attributing it to an unforeseeable event rather than a systemic issue. Cramer underscored his unwavering faith in Kimberly-Clark's CEO, Mike Hsu, suggesting that Hsu's strategic direction, combined with the beneficial acquisition of Kenvue, will enhance the company's overall value. Despite the stock trading at 13 times its earnings, Cramer encouraged investors to consider purchasing more shares, advocating for an 'average down' strategy for those already invested, implying a belief in the company's underlying strength and future growth potential.

This insight from Jim Cramer provides a valuable perspective for investors, particularly those seeking dividend-paying stocks with a strong fundamental outlook. His emphasis on KMB's dividend yield, management's capability, and strategic acquisitions suggests a belief in the company's resilience and capacity for sustained growth. While past performance is not indicative of future results, a seasoned analyst's conviction can certainly influence market sentiment and spark further investigation into such opportunities.

T. Harv Eker
authorBy T. Harv Eker

Author of "Secrets of the Millionaire Mind," focusing on the mindset and psychology of wealth.

Other Articles

Keefe Bruyette Adjusts Price Target for KKR Real Estate Finance Trust (KREF)Apr 12, 2026

Keefe Bruyette Adjusts Price Target for KKR Real Estate Finance Trust (KREF)

Keefe Bruyette recently revised its price target for KKR Real Estate Finance Trust (KREF) to $7 from $8, maintaining a 'Market Perform' rating. This adjustment follows KREF's significant lease agreement with OpenAI for a five-building campus in Mountain View, California. Additionally, Citizens also lowered its price target on KREF to $9.50 from $10, citing the company's aggressive approach to resolving watch list loans and selling REO properties.

Natalie PaceBy Natalie Pace
Astera Labs: Is the AI Infrastructure Leader Still a Top Growth Pick?Apr 12, 2026

Astera Labs: Is the AI Infrastructure Leader Still a Top Growth Pick?

Despite Citi's recent price target reduction for Astera Labs (ALAB) due to AI valuation adjustments, the firm maintains a 'Buy' rating, highlighting the company's strong potential in the expanding AI scale-up trend. Astera Labs, a crucial provider of high-performance connectivity solutions for AI data centers, is expected to benefit significantly from its PCIe switch business, particularly the Scorpio family, and co-packaged optics. Analyst sentiment remains overwhelmingly positive, with a substantial upside projected from current levels.

Bola SokunbiBy Bola Sokunbi
Despite Phase 3 Setback, Analysts Maintain Positive Outlook on Gossamer Bio (GOSS)Apr 12, 2026

Despite Phase 3 Setback, Analysts Maintain Positive Outlook on Gossamer Bio (GOSS)

Gossamer Bio (GOSS) has garnered continued analyst confidence, with 56% issuing "Hold" ratings and a consensus price target suggesting a substantial upside of over 200%. This comes despite a Phase 3 trial failure for its drug seralutinib, leading to regulatory uncertainty. The company is reevaluating its strategy and has sufficient capital to fund operations into early 2027.

Scott PapeBy Scott Pape